drugset
drugset / Trial / NCT03650738

This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment

NCT03650738 ↗

Phase 2 Unknown 60 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

This study was a prospective, one-arm open phase II clinical trial. A systematic review of the pCR of apatinib in combination with the albumin paclitaxel and carboplatin regimens for the neoadjuvant therapy of triple-negative breast cancer, as well as the safety of treatment, at the same time, relevant exploratory biomarker research is conducted.

Timeline

Start
2018-09-01
Primary completion
2019-12-30
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin paclitaxel Unknown 260 mg/m2 Intravenous
Subject Carboplatin Small molecule — Intravenous
Subject Rivoceranib Small molecule 250 mg Oral

Indications

No indication recorded.